Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001127602-12-015940)

Filing Details

Accession Number:: 0001127602-12-015940
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2012-05-04 16:29:07
Reporting Period:: 2012-05-02

Filing Date:: 2012-05-04
Accepted Time:: 2012-05-04 16:29:07
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
884731	Ariad Pharmaceuticals Inc	ARIA	Biological Products, (No Disgnostic Substances) (2836)	223106987

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1494892	Frank Haluska	C/O Ariad Pharmaceuticals, Inc. 26 Landsdowne Street Cambridge MA 02139	Svp, Clinical R&D, Cmo	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-05-02	3,000	$2.39	52,781	No	4	M	Direct
Common Stock	Disposition	2012-05-02	3,000	$17.00	49,781	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2012-05-02	3,000	$0.00	3,000	$2.39

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
19,500	2009-06-12	2018-06-12	No	4	M	Direct

Footnotes

Shares were acquired upon the exercise of outstanding stock options at $2.39 per share.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2011.